Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice

Salari, Farhad; Varasteh, Abdolreza; Vahedi, Fatemeh; Hashemi, Maryam; Sankian, Mojtaba

doi:10.1016/j.intimp.2015.09.011

Cited by 35 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this sense, besides antigen penetration across the sublingual epithelial barrier, an active capture by intraepithelial DCs25 or through the ductal epithelial cells26 has been described, even for particulate antigens, silica beads, or microbes 26. In fact, bigger structures than PM‐allergoids, like particles of different sizes15, 27 or whole cell bacteria,28, 29 have also been successfully used for immunization through the sublingual route.…”

Section: Discussionmentioning

confidence: 99%

“…Allergen uptake by oral mucosal dendritic cells (DCs) is thought to be a critical step for initiating the immune response in SLIT,11 a step requiring higher allergen concentration and dose frequency for SLIT than SCIT 12. To improve allergen uptake by oral DCs, some experimental allergen formulations have been assayed, such as conjugation with cholera toxin,13 binding to mucoadhesive agents,14 or using nanoparticles 15…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice

Soria

López-Relaño

Viñuela

et al. 2018

Allergy

View full text Add to dashboard Cite

BackgroundPolymerized allergoids coupled to nonoxidized mannan (PM‐allergoids) may represent novel vaccines targeting dendritic cells (DCs). PM‐allergoids are better captured by DCs than native allergens and favor Th1/Treg cell responses upon subcutaneous injection. Herein we have studied in mice the in vivo immunogenicity of PM‐allergoids administered sublingually in comparison with native allergens.MethodsThree immunization protocols (4‐8 weeks long) were used in Balb/c mice. Serum antibody levels were tested by ELISA. Cell responses (proliferation, cytokines, and Tregs) were assayed by flow cytometry in spleen and lymph nodes (LNs). Allergen uptake was measured by flow cytometry in myeloid sublingual cells.ResultsA quick antibody response and higher IgG2a/IgE ratio were observed with PM‐allergoids. Moreover, stronger specific proliferative responses were seen in both submandibular LNs and spleen cells assayed in vitro. This was accompanied by a higher IFNγ/IL‐4 ratio with a quick IL‐10 production by submandibular LN cells. An increase in CD4+ CD25high FOXP3+ Treg cells was detected in LNs and spleen of mice treated with PM‐allergoids. These allergoids were better captured than native allergens by antigen‐presenting (CD45+ MHC‐II +) cells obtained from the sublingual mucosa, including DCs (CD11b+) and macrophages (CD64+). Importantly, all the differential effects induced by PM‐allergoids were abolished when using oxidized instead of nonoxidized PM‐allergoids.ConclusionOur results demonstrate for the first time that PM‐allergoids administered through the sublingual route promote the generation of Th1 and FOXP3+ Treg cells in a greater extent than native allergens by mechanisms that might well involve their better uptake by oral antigen‐presenting cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice

Soria

López-Relaño

Viñuela

et al. 2018

Allergy

View full text Add to dashboard Cite

show abstract

“…More interestingly, it has been reported that PLGA facilitated immune vaccine delivery can enhance the immune response of T helper 1 (Th1) and require less allergen dose for effective sublingual immunotherapy. [ 62 ]…”

Section: Structural Designs Of Polymeric Nonviral Gene Delivery Systemsmentioning

confidence: 99%

Polymeric Nonviral Gene Delivery Systems for Cancer Immunotherapy

Cai

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Unlike viral vectors with their undesired safety or immunogenicity concerns, biocompatible polymeric nonviral vectors as gene delivery systems are more promising in gene or cell therapy. Evidence has demonstrated that the rational design of polymeric nonviral gene vectors with optimal structure, charge density, biocompatibility, and stimulus responsiveness can deliver therapeutic genes or gene vaccines (in terms of deoxyribonucleic acid DNA or ribonucleic acid RNA) into tumor‐associated immunocytes (i.e., macrophages, T cells, or dendritic cells) in an effective and controllable manner for enhanced cancer immunotherapy. However, a timely and systematic summary of this subject is lacking. This review presents an overview of polymeric nonviral carriers with immune cell transfection ability and their potential applications in cancer immunotherapy; it also provides a tutorial for designing polymeric immune‐cell genetic modification vector, although there are still few vectors in the product pipeline. With the rapid growth of immunotherapy in cancer treatment and knowledge accumulation in vector structure design, polymeric nonviral gene delivery systems may provide new hope for tumor therapy.

show abstract

“…However, these ratios were similar for each particle size (200, 500, and 1000 nm) among the subcutaneous, oral, and intranasal routes . Recently, it was shown that PLGA‐encapsulated rChe a 3 allergen with 400 nm size could significantly enhance systemic T regulatory (Treg) and T helper 1 (Th1) immune responses by sublingual administration . Some factors which could be affected on the size, encapsulation efficiency, release, and stability of antigen‐encapsulated PLGA particles include solvent, sonication time, polymer properties, stabilizers, osmolytes, and insoluble metal complexes, addition of several proteins, salts, surfactants, and chemical modification.…”

Section: Strategies For Improvement Of Antigen Delivery Using Plga Pamentioning

confidence: 99%

Optimization of PLGA formulation containing protein or peptide‐based antigen: Recent advances

Hajavi

Ebrahimian

Sankian

et al. 2018

J Biomedical Materials Res

Self Cite

View full text Add to dashboard Cite

Protein or peptide-based antigens are the most promising forms to generate custom protective immune responses for clinical applications. Over the last decades, poly(lactic-co-glycolic acid) (PLGA) as a biodegradable polymer has gained more attention for delivery of protein and peptide. Besides many appropriate characteristics, to improve its properties to overcome some obstacles such as release profile and it is important instability of antigen during both encapsulation and storage. Therefore, optimized procedures conditions require to be used to maintain the integrity of protein structure under several stress factors in formulation process. In this review article, the properties of PLGA particles, their preparation techniques and strategies for improvement of protein stability during encapsulation into PLGA, release from particle and storage as well as stabilization approaches were summarized. © 2018 Wiley Periodicals, Inc. J. Biomed. Mater. Res. Part A: 106A: 2540-2551, 2018.

show abstract

Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice

Cited by 35 publications

References 51 publications

Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice

Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice

Polymeric Nonviral Gene Delivery Systems for Cancer Immunotherapy

Optimization of PLGA formulation containing protein or peptide‐based antigen: Recent advances

Contact Info

Product

Resources

About